West Pharmaceutical Services (WST): financials, SEC filings and peers
West Pharmaceutical Services (WST) is a health care supplies company in the Health Care sector of the S&P 500, headquartered in Exton, Pennsylvania.
It was founded in 1923 and joined the S&P 500 on May 22, 2020.
Its fiscal year ends in December, and its shares trade on the NYSE.
In its SEC filings it is classified as “Surgical & Medical Instruments & Apparatus”.
West Pharmaceutical Services at a glance
- Revenue (12 months)
- $3.3B
- Revenue growth
- +12.4%
- Operating margin
- 20.5%
- Net income (12 months)
- $565M
- Free cash flow (12 months)
- $437M
- Cash
- $436M
- Debt
- $203M
- Diluted EPS (12 months)
- $7.81
Twelve months to June 30, 2026, from the 10-Q filed July 23, 2026.
Latest twelve months
Over the twelve months to June 30, 2026, West Pharmaceutical Services reported revenue of $3.3 billion, up 12.4% from a year earlier.
Its operating margin was 20.5%: for every $100 of sales, about $20 was left as operating profit.
Net income was $565 million (17.0% of revenue), 15.8% higher than a year earlier.
Operating cash flow was $662 million and capital spending $225 million, leaving free cash flow of $437 million (13.1% of revenue).
At the end of the period it held $436 million in cash and $203 million in debt, a net cash position of $233 million.
The diluted share count fell 1.7% in a year, typically the result of buybacks.
Five-year trend
- Revenue went from $2.1 billion in fiscal 2020 to $3.1 billion in fiscal 2025, about 7.4% a year.
- Operating margin has been steady, around 19.0%.
- Free cash flow was positive in each of the last 6 fiscal years.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $2.8B | $2.9B | $2.9B | $2.9B | $3.1B |
| Revenue growth | 31.9% | 2.0% | 2.2% | -1.9% | 6.3% |
| Operating margin | 26.6% | 25.4% | 22.9% | 19.7% | 19.0% |
| Net income | $662M | $586M | $593M | $493M | $494M |
| Free cash flow | $331M | $439M | $415M | $276M | $469M |
| Diluted EPS | $8.67 | $7.73 | $7.88 | $6.69 | $6.79 |
Fiscal years as reported in West Pharmaceutical Services’s 10-K filings. Free cash flow is operating cash flow minus capital spending.
Recent SEC filings
- 10-Q filed July 23, 2026 — quarterly report
- 8-K filed July 23, 2026 — Earnings results; Regulation FD disclosure
- 8-K filed July 14, 2026 — Material agreement
- 8-K filed June 1, 2026 — Executive or director change; Regulation FD disclosure
- 8-K/A filed May 20, 2026
- 8-K filed May 11, 2026 — Regulation FD disclosure
- 8-K filed May 5, 2026 — Shareholder vote results
- 10-Q filed April 23, 2026 — quarterly report
Companies like West Pharmaceutical Services
Other S&P 500 companies in Health Care Supplies:
More from Health Care
Questions about West Pharmaceutical Services
Is West Pharmaceutical Services's revenue growing?
Yes. Revenue for the twelve months to June 30, 2026 was $3.3 billion, up 12.4% from a year earlier, according to its SEC filings.
Is West Pharmaceutical Services profitable?
Yes. It earned $565 million in net income over the twelve months to June 30, 2026, a net margin of 17.0%.
Does West Pharmaceutical Services have more cash or more debt?
At June 30, 2026 it had $436 million in cash and $203 million in debt, so more cash than debt.
When did West Pharmaceutical Services last file financial results?
Its latest quarterly report (10-Q) was filed with the SEC on July 23, 2026.
Which companies are similar to West Pharmaceutical Services?
In the S&P 500, West Pharmaceutical Services is grouped in Health Care Supplies within the Health Care sector. Align Technology (ALGN), Cooper Companies (The) (COO) are in the same group.
Understand the numbers
Source: West Pharmaceutical Services’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved September 27, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.